Merus NV (MRUS) Expected to Announce Quarterly Sales of $2.72 Million

Wall Street brokerages expect Merus NV (NASDAQ:MRUS) to post sales of $2.72 million for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Merus’ earnings, with the lowest sales estimate coming in at $2.05 million and the highest estimate coming in at $3.40 million. Merus reported sales of $1.20 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 126.7%. The company is expected to announce its next quarterly earnings report on Friday, April 27th.

On average, analysts expect that Merus will report full-year sales of $2.72 million for the current financial year, with estimates ranging from $13.59 million to $14.35 million. For the next financial year, analysts anticipate that the company will post sales of $17.28 million per share, with estimates ranging from $8.19 million to $26.37 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that cover Merus.

Several analysts have recently issued reports on MRUS shares. Royal Bank of Canada reaffirmed a “buy” rating and set a $28.00 price objective on shares of Merus in a report on Wednesday, October 18th. Zacks Investment Research cut Merus from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. Jefferies Group restated a “buy” rating and set a $30.00 price target on shares of Merus in a report on Thursday, October 26th. Finally, ValuEngine lowered Merus from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company. Merus has a consensus rating of “Hold” and a consensus target price of $30.25.

A hedge fund recently bought a new stake in Merus stock. Renaissance Technologies LLC bought a new position in Merus NV (NASDAQ:MRUS) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 22,500 shares of the biotechnology company’s stock, valued at approximately $549,000. Renaissance Technologies LLC owned 0.14% of Merus as of its most recent SEC filing. 30.07% of the stock is owned by institutional investors.

Shares of Merus (MRUS) traded up $0.05 on Thursday, hitting $15.31. The stock had a trading volume of 48,500 shares, compared to its average volume of 30,057. The stock has a market cap of $296.65 and a PE ratio of -2.27. Merus has a twelve month low of $13.23 and a twelve month high of $33.63.

ILLEGAL ACTIVITY WARNING: This piece was reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.com-unik.info/2017/12/28/merus-nv-mrus-expected-to-announce-quarterly-sales-of-2-72-million.html.

About Merus

Get a free copy of the Zacks research report on Merus (MRUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Merus (NASDAQ:MRUS)

What are top analysts saying about Merus? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Merus and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit